[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649457":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":37,"centralContacts":41,"locations":47,"responsibleParty":130,"collaborators":45,"id":132,"slug":133,"hasResults":134,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":134,"sex":140,"minAge":141,"maxAge":45,"enrollmentInfo":142,"targetDuration":45,"studyType":145,"phases":146,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":50,"whyStopped":45,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":168},{"fullName":5,"class":6},"Kodiak Sciences Inc","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Tabirafusp tedromer 5 mg Q8W","EXPERIMENTAL","Intravitreal injection of tabirafusp tedromer once every 4 weeks for 6 monthly doses followed by every-8-week dosing with additional individualized dosing (up to monthly dosing)",[13],"Drug: Tabirafusp tedromer",{"label":15,"type":10,"description":16,"interventionNames":17},"Tabirafusp tedromer 5 mg Q4-24W","Intravitreal injection of tabirafusp tedromer once every 4 weeks for 6 monthly doses followed by individualized dosing every 4 to 24 weeks.",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Aflibercept 2 mg","ACTIVE_COMPARATOR","Intravitreal injection of aflibercept once every 4 weeks for 5 monthly doses followed by every-8-week dosing",[23],"Drug: Aflibercept (2.0 mg)",[25,32],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Tabirafusp tedromer","Intravitreal injection",[15,9],[31],"KSI-501",{"type":26,"name":33,"description":28,"armGroupLabels":34,"otherNames":35},"Aflibercept (2.0 mg)",[19],[36],"Eylea",[38],{"name":39,"affiliation":5,"role":40},"J. Pablo Velazquez-Martin, MD","STUDY_DIRECTOR",[42],{"name":5,"role":43,"phone":44,"phoneExt":45,"email":46},"CONTACT","6502810850",null,"ClinicalTrials@kodiak.com",[48,62,70,79,88,97,106,114,122],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":45},"Kodiak Research Center","RECRUITING","Glendale","California","91204","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-118.25508,34.14251,{"lat":60,"lon":59},{"facility":49,"status":50,"city":63,"state":52,"zip":64,"country":54,"countryCode":55,"cosmosGeoPoint":65,"geoPoint":69,"contacts":45},"Pasadena","91107",{"type":57,"coordinates":66},[67,68],-118.14452,34.14778,{"lat":68,"lon":67},{"facility":49,"status":50,"city":71,"state":72,"zip":73,"country":54,"countryCode":55,"cosmosGeoPoint":74,"geoPoint":78,"contacts":45},"St. Petersburg","Florida","33711",{"type":57,"coordinates":75},[76,77],-82.67927,27.77086,{"lat":77,"lon":76},{"facility":49,"status":50,"city":80,"state":81,"zip":82,"country":54,"countryCode":55,"cosmosGeoPoint":83,"geoPoint":87,"contacts":45},"Hagerstown","Maryland","21740",{"type":57,"coordinates":84},[85,86],-77.71999,39.64176,{"lat":86,"lon":85},{"facility":49,"status":50,"city":89,"state":90,"zip":91,"country":54,"countryCode":55,"cosmosGeoPoint":92,"geoPoint":96,"contacts":45},"Saint Louis Park","Minnesota","55416",{"type":57,"coordinates":93},[94,95],-93.34801,44.9483,{"lat":95,"lon":94},{"facility":49,"status":50,"city":98,"state":99,"zip":100,"country":54,"countryCode":55,"cosmosGeoPoint":101,"geoPoint":105,"contacts":45},"Beaufort","South Carolina","29902",{"type":57,"coordinates":102},[103,104],-80.66993,32.4317,{"lat":104,"lon":103},{"facility":49,"status":50,"city":107,"state":99,"zip":108,"country":54,"countryCode":55,"cosmosGeoPoint":109,"geoPoint":113,"contacts":45},"Charleston","29414",{"type":57,"coordinates":110},[111,112],-79.93275,32.77632,{"lat":112,"lon":111},{"facility":49,"status":50,"city":115,"state":99,"zip":116,"country":54,"countryCode":55,"cosmosGeoPoint":117,"geoPoint":121,"contacts":45},"Ladson","29456",{"type":57,"coordinates":118},[119,120],-80.10981,32.98573,{"lat":120,"lon":119},{"facility":49,"status":50,"city":123,"state":99,"zip":124,"country":54,"countryCode":55,"cosmosGeoPoint":125,"geoPoint":129,"contacts":45},"West Columbia","29169",{"type":57,"coordinates":126},[127,128],-81.07398,33.99349,{"lat":128,"lon":127},{"type":131,"investigatorFullName":45,"investigatorTitle":45,"investigatorAffiliation":45,"oldNameTitle":45,"oldOrganization":45},"SPONSOR","100649457","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-tabirafusp-tedromer-compared-to-aflibercept-in-participants-with-dme---alto-100649457",false,"NCT07734844","A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO","A Randomized, Double-masked, Active-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Tedromer 5 mg Compared With Intravitreal Aflibercept 2 mg in Participants With Visual Impairment Secondary to Diabetic Macular Edema (DME) - ALTO","ALTO","Inclusion Criteria:\n\n* DME, treatment-naïve or previously-treated\n* Male or female ≥18 years of age with Type 1 or Type 2 diabetes mellitus and a HbA1c of ≤12%\n* Capable of giving informed signed consent\n\nExclusion Criteria:\n\n* Active iris or angle neovascularization or neovascular glaucoma in the Study Eye.\n* Current or history of retinal detachment (tractional or rhegmatogenous) in the Study Eye","ALL","18 Years",{"count":143,"type":144},910,"ESTIMATED","INTERVENTIONAL",[147],"PHASE3","A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants with Diabetic Macular Edema - ALTO",[150],"Diabetic Macular Edema (DME)",[152,31,153,154,155,156,157,158],"DME","tabirafusp tedromer","aflibercept","antibody biopolymer conjugate","anti-VEGF","anti-IL-6","Kodiak Sciences","2026-08-19",{"date":161,"type":162},"2026-08-21","ACTUAL",{"date":164,"type":162},"2026-08-03",{"date":166,"type":144},"2029-09",{"name":5,"class":6},9]